Ultragenyx Pharma (RARE) PT Lowered to $70 at Baird; Multiple Milestones Ahead
Baird lowered its price target on Ultragenyx Pharma (NASDAQ: RARE) to $70.00 (from $80.00) while maintaining an Outperform rating.
Analyst Michael Ulz notes building momentum with multiple commercial and clinical milestones in 2018.
"Notable catalysts remain on track for UX007, including potential for early filing in FAOD (update mid-2018) and Phase 3 data in Glut 1 DS movement (2H18)," he commented.